Foamix Receives Approval For Rosacea Drug

August 3, 2015 | Foamix Pharmaceuticals received approval for its product that treats Rosacea. The development license for the product was granted to Bayer, the international pharmaceutical company that carried out the clinical trials and registered Foamix’s product for marketing. As part of the deal with Bayer, Foamix will receive payments which its estimates will reach a value of $10 million in total. Foamix is the developer of foam-based drugs and was founded in 2003 by Dov Tamarkin.